MA-BATTERY-VENTURES
17.4.2024 12:01:33 CEST | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, announced the acquisition of Labguru (BioData Inc.), the life-science laboratory-data platform, from Holtzbrinck Digital. Terms were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417562351/en/
Labguru provides a comprehensive laboratory data-management hub for planning and tracking; documenting experiments; streamlining lab logistics; and sharing results across teams and organizations. Labguru’s easy-to-use, cloud-based, research-to-production life-science platform combines an Electronic Lab Notebook (ELN), a Laboratory Information Management System (LIMS) and a set of informatics tools to enable and enhance research and production. Labguru is trusted by hundreds of thousands of scientists across the biotechnology, pharmaceutical and advanced-industry segments, as well as researchers at global academic and research institutions.
Labguru will join Battery’s Titian Software to create a global organization that offers an end-to-end solution across life sciences and laboratory applications from research to production, spanning the entire workflow from ELN to inventory and sample management, research, testing and QC workflows.
“Together Titian and Labguru will use the investment by Battery to further support organic growth as well as shape the direction of the group’s future acquisitions, in fulfilling the group vision to become the one-stop shop of the global life-science software market,” said Battery General Partner Jesse Feldman.
“We are excited to bring together Titian and Labguru and to work with the companies’ leaders to provide an integrated laboratory and sample-management offering to researchers,” Feldman said. “The two companies already serve researchers across multiple disciplines at the forefront of science, and we look forward to expanding how we serve our customers.”
Labguru’s executive team, including CEO Ariel Yarnitsky and founder and CTO Jonathan Gross, will remain in their current roles, working alongside the Titian executive team following the transaction.
“We’re excited to join forces with Battery, a long-standing investor with domain expertise across life-science informatics and laboratory automation and leverage their vast experience during Labguru’s next growth phase,” said Yarnitsky. “Specifically, Labguru’s mission to build a leading solution catering to the broad needs of scientists in one coherent and easy-to-use platform becomes even more exciting by joining hands with Titian and with the strong support of Battery. Between the additional capital from Battery and the product and cultural fit with Titian, we could not think of a more suitable partner to propel Labguru forward.”
Founder Gross added: “Partnering with Battery and Titian will accelerate our ability to leverage technology, experience and insights to effectively widen the scope of our platform, benefiting science and scientists. This is an important and dramatic step in Labguru’s journey. Further, with Battery Ventures’ long-standing experience investing in data and AI companies, we have found a valuable partner to help shape our vision as we continue building on Labguru’s suite of artificial intelligence tools.”
Titian Software Founder and Chief Product Officer Edmund Wilson added, “We are delighted to partner with Labguru. Our companies share a common commitment to providing state-of-the-art solutions to the life sciences community, delivered by staff who offer tremendous domain expertise.”
Holtzbrinck Digital played a crucial role in Labguru's development and success. Their vision and support have been instrumental in the company's fast growth and positioning as a tier-1 lab-management software company. "We are extremely happy with Labguru's development over the last years and are proud of the strides we've made together. Finding a partner like Battery, who shares our commitment to innovation and excellence, marks a thrilling next chapter for Labguru," said Marc-Orell Dedorath, head of group M&A at Holtzbrinck.
“We are thrilled to unite two major forces in a market that's only beginning to realize its vast potential,” added Justin Rosner, a principal at Battery. “We look forward to working with the Labguru and Titian teams as we embark on this journey together."
About Labguru (BioData Inc.)
Labguru (BioData Inc.) was founded in 2007 and is the developer of a secure, cloud-based laboratory data management platform for life science research and industry. Labguru is an all-in-one platform that streamlines laboratory operations by recording and managing data and inventory, offering molecular biology and chemistry tools, enabling lab automation, and providing data-driven, AI-assisted insights for increased efficiency. As a trusted tool for more than 120,000 scientists worldwide, we empower the digitalization efforts of customers ranging from start-ups to global life science organizations. To learn more about Labguru, visit www.labguru.com.
About Titian Software
Titian Software was founded in 1999 and is a leading provider of sample management software solutions, catering to the unique needs of research laboratories, biobanks, and pharmaceutical companies worldwide. Titian's Mosaic Sample Management Software encompasses a comprehensive suite of tools for sample tracking, inventory management, and workflow automation. Mosaic empowers laboratories to efficiently manage vast repositories of samples, including compounds, biological materials, and clinical specimens while ensuring data integrity and traceability throughout the sample lifecycle. www.titian.co.uk.
About Battery Ventures
Battery partners with exceptional founders and management teams, developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT, and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Tel Aviv; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com, and find a complete list of Battery's portfolio companies here.
About Holtzbrinck Digital
Holtzbrinck Digital manages the investments of the Holtzbrinck Publishing Group in digital startups in the science and education sector, as well as other areas of strategic importance. Holtzbrinck Digital supports them in their development with expertise, resources, and a long-term commitment, enabling the companies to achieve the best possible development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417562351/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom